

- Previous studies have shown the 0.59-mg fluocinolone acetonide (FA) intravitreal implant (Retisert<sup>®</sup>, Bausch + Lomb, Rochester, NY, USA) to be efficacious in the treatment of noninfectious posterior uveitis (NIPU) in a primarily Caucasian population.
- The results of this study confirm the efficacy of the 0.59-mg FA implant in a primarily Asian population with NIPU.
- The 0.59-mg FA implant led to significantly reduced uveitis recurrence rates relative to the pre-implantation period, improved visual acuity compared to nonimplanted eyes, and reductions in adjunctive therapy including systemic therapy and/or periocular injections.
- Elevations of intraocular pressure were frequent and nearly all phakic implanted eyes required cataract surgery.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Bausch + Lomb. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).